Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Chelsea Pruckner"'
Publikováno v:
Case Reports in Oncological Medicine, Vol 2015 (2015)
On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor
Externí odkaz:
https://doaj.org/article/5581e610eef44837b66b97ff93111b37
Publikováno v:
Case Reports in Oncological Medicine, Vol 2015 (2015)
Case Reports in Oncological Medicine
Case Reports in Oncological Medicine
On the basis of remarkable antitumor activity, programmed death receptor-1 (PD-1) inhibitors pembrolizumab and nivolumab were approved for the treatment of advanced melanoma in the second-line setting following progression on either CTLA-4 inhibitor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5f073aa82fd985ba0fa9d12c85dd539
https://doi.org/10.1155/2015/737389
https://doi.org/10.1155/2015/737389
Autor:
Amy Rose, Chelsea Pruckner, Diwakar Davar, Ling Tian, John M. Kirkwood, Melissa Wilson, Fei Ding, Ahmad A. Tarhini, Cindy Sander
Publikováno v:
Journal of Clinical Oncology. 34:e21042-e21042
e21042Background: Uveal and mucosal melanomas are rare subtypes with a mean age-adjusted incidence of 5.6 and 2.3 cases per million person-years. Metastatic uveal and mucosal patients (pts) tend to...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ef51b7b83ffa12663b8cb5515d90261
https://doi.org/10.1200/jco.2016.34.15_suppl.e21042
https://doi.org/10.1200/jco.2016.34.15_suppl.e21042
Autor:
Andrew Gnan, John M. Kirkwood, Yan Lin, Chelsea Pruckner, Uma N. M. Rao, Zahra Rahman, Amy Rose, James F. Pingpank, Melissa Wilson, Hussein Abdul-Hassan Tawbi, Robert L. Ferris, Priyanka Vallabhaneni, Matthew P. Holtzman, Amanda McFadden, Ahmad A. Tarhini
Publikováno v:
Journal of Clinical Oncology. 34:9585-9585
9585Background: Neoadjuvant ipilimumab (ipi) at 3 or 10 mg/kg in combination with high dose IFNα2b (HDI) for locally/regionally advanced or recurrent melanoma may improve the clinical outcomes of t...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8f9c077decafc7308597a1785f196f1
https://doi.org/10.1200/jco.2016.34.15_suppl.9585
https://doi.org/10.1200/jco.2016.34.15_suppl.9585